Corvion develops a fully implanted mechanical circulatory support device, the CORVION LVAD, designed for severe heart failure patients. This system features a high-efficiency pump powered by a small, implantable battery allowing for up to 12 hours of untethered operation. The technology eliminates the need for percutaneous drivelines, offering patients greater mobility and a reduced risk of infection.
Funding
$917.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with severe heart failure requiring mechanical circulatory support often face significant lifestyle limitations due to bulky external equipment, percutaneous drivelines, and frequent recharging requirements. These factors increase the risk of infection and restrict daily activities, impacting overall quality of life.
Solution
Corvion is developing a fully implantable Left Ventricular Assist Device (LVAD) designed to restore mobility and reduce the burden of care for severe heart failure patients. The system features a high-efficiency pump, powered by a small, implantable battery that provides up to 12 hours of untethered operation. Wireless charging eliminates the need for external cables and connectors, minimizing infection risk and enabling patients to bathe and sleep without interruption. This integrated approach aims to facilitate a more normal lifestyle by reducing external hardware and improving patient autonomy.
Target Audience
The primary target audience includes cardiologists, cardiac surgeons, and hospital systems specializing in advanced heart failure management and mechanical circulatory support.
Features
- Fully implantable mechanical circulatory support system for severe heart failure
- High-efficiency pump utilizing a hybrid magnetically levitated impeller and optimized motor design, requiring 3x less power than competing devices
- Small, implantable battery and controller unit enabling up to 12 hours of untethered operation
- Wireless charging system for the implanted power source, requiring 2 hours for a full recharge without external cables or precise alignment
- Elimination of percutaneous drivelines to reduce infection risk and improve patient comfort
- Discreet physical profile and reduced external equipment for enhanced patient mobility and quality of life